Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child–Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria

2020 ◽  
Author(s):  
Xi Xu ◽  
Xingyu Pu ◽  
Li Jiang ◽  
Yang Huang ◽  
Lunan Yan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
San Francisco ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
University Of California ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Ucsf Criteria ◽  
The University

scholarly journals Clinical efficacy of locoregional therapy prior to living donor liver transplantation for hepatocellular carcinoma based on UCSF criteria

2019 ◽  
Author(s):  
Tsung-Han Wu ◽  
Chih-Hsien Cheng ◽  
Chen-Fang Lee ◽  
Ting-Jung Wu ◽  
Hong-Shiue Chou ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
San Francisco ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Locoregional Therapy ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Regional Therapy ◽  
Ucsf Criteria

Abstract Background The study analyzed the loco-regional therapy outcomes prior to living donor liver transplantation (LDLT), to provide additional information for decision-making regarding therapeutic strategy for hepatocellular carcinoma (HCC) patients. Methods A total of 308 consecutive patients undergoing LDLTs for HCC between August 2004 and December 2018 were retrospectively analyzed. Patients subjected to loco-regional therapy prior to LT were grouped and the outcomes were compared. Results Overall, HCC recurrence after LDLT were detected in 38 patients (12.3%) during the follow-up period. By the end of the study, 205 patients, 6 of whom with recurrent HCC, were alive. Patients who had radiological imaging beyond the University of California at San Francisco (UCSF) criteria had significant inferior outcomes for both recurrence-free survival (RFS, p = 0.0005) and overall survival (OS, p = 0.0462) despite receiving loco-regional therapy as down-staging intention. Moreover, patients with profound tumor necrosis (TN) had a superior RFS at 3 and 5 years (97.4% and 93.8%, respectively), compared with others. Conclusion LDLT gains a satisfactory result based on the expanded UCSF criteria for HCC. However, the loco-regional therapy prior to LDLT does not seem to provide benefit unless a profound TN is noted.

scholarly journals Living Donor Liver Transplantation Outcomes for Hepatocellular Carcinoma Beyond Milan or UCSF Criteria

2014 ◽  
Vol 77 (S3) ◽  
pp. 950-956 ◽  
Author(s):  
Yusuf Gunay ◽  
Necdet Guler ◽  
Onur Yaprak ◽  
Murat Dayangac ◽  
Murat Akyildiz ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Ucsf Criteria ◽  
Transplantation Outcomes

Living Donor Liver Transplantation for Hepatocellular Carcinoma in Patients Exceeding the UCSF Criteria

2008 ◽  
Vol 40 (9) ◽  
pp. 3185-3188 ◽  
Author(s):  
I. Fouzas ◽  
G.C. Sotiropoulos ◽  
H. Lang ◽  
S. Nadalin ◽  
S. Beckebaum ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Ucsf Criteria

A case of hepatocellular carcinoma relapsed 44 months after living donor liver transplantation, with a 50-month survival thereafter by multimodal treatments

Kanzo ◽  
2009 ◽  
Vol 50 (4) ◽  
pp. 192-200
Author(s):  
Hiroko Oka ◽  
Osamu Yamazaki ◽  
Katsuhiko Horii ◽  
Takao Manabe ◽  
Kiyohide Kioka ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Donor Liver ◽  
Donor Liver Transplantation
Sign in / Sign up

Export Citation Format

Share Document